| Antigen | Clone | Application |
|---|---|---|
| CD11a | MEM-83 | The antibody MEM-83 directly induces the binding of T cells to purified ICAM-1. Using an in vitro-translated CDlla cDNA deletion series, the MEM-83 activation epitope was mapped to the "I" domain of the LFA-1 alpha subunit. The studies have therefore identified a novel LFA-1 activation epitope mapping to the I domain of LFA-1, which could play a role in the regulation of LFA-1 binding to ICAM-1. |
| CD11a | MEM-25 | The antibody MEM-25 partially blocks binding of LFA-1 complex to ICAM-1. |
| CD11b | MEM-170 | The antibody MEM-170 blocks (not completely) Mac-1-mediated neutrophil binding to fibrinogen. |
| CD11b | M1/70 | In vitro blocking of CD11b |
| CD13 | WM15 | The antibody WM15 inhibits infection of cells by human coronavirus and inhibits aminopeptidase N activity of the CD13 molecule immunoprecipitates. |
| CD14 | MEM-18 | The antibody MEM-18 completely blocks binding of fluorescein (FITC) – labeled bacterial LPS to the monocyte surface and it also blocks the binding of CD14 to the extracellular TLR2 domain. |
| CD147 | MEM-M6/6 | The antibody MEM-M6/6 (high-affinity mAb of unique epitope specificity) inhibits anti-CD3-induced T cell activation. |
| CD16b | MEM-154 | The antibody MEM-154 blocks binding of human IgG to FcgammaRIII. |
| CD18 | MEM-148 | The antibody MEM-148 induces homotypic cell aggregation and high-affinity LFA-1 conformation in resting leukocytes. |
| CD18 | MEM-48 | The antibody MEM-48 induces high-affinity conformation of LFA-1 complex. |
| CD19 (mouse) | 1D3 | This cantibody can induce down-regulation of CD19, affecting the proportions of B cell subpopulations. |
| CD253 / TRAIL | 2E5 | The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays. |
| CD261 / TRAIL-R1 | DR-4-02 | Soluble antibody DR-4-02 blocks apoptosis triggered by a ligand (TRAIL). Plastic-immobilized (cross-linked) DR-4-02 antibody induces apoptosis in sensitive cells. Recommended dilution of antibody: 2-3 μg/ml in cultivation medium Final concentration of TRAIL: 20-200 ng/ml Application note: It is recommended to add the antibody 15 min before addition of TRAIL. |
| CD28 | CD28.2 | T cell costimulation |
| CD28 (mouse) | 37.51 | In vitro and in vivo T cell costimulation |
| CD3 | MEM-92 | The antibody MEM-92 in solution induces early responses of T cell activation (tyrosine phosphorylation, calcium elevation, Erk activation and expression of activation antigens), but it is unable to induce T cell proliferation. |
| CD3 | UCHT1 | The immobilized UCHT1 antibody initiates a signaling pathway resulting in T cell activation and proliferation. |
| CD3 | MEM-57 | The antibody MEM-57 has strong mitogenic effect on peripheral T lymphocytes; it reacts strongly with gamma/delta T lymphocytes. |
| CD3 (mouse) | 145-2C11 | Induction of T cell activation, proliferation or apoptosis (depending on conditions); in vivo T cell depletion |
| CD34 | QBEnd-10 | The antibody QBEnd-10 induces homotypic adhesion of leukemic cell line. |
| CD4 | MEM-115 | The antibody MEM-115 blocks binding of HIV gp120 to CD4 molecule and it also strongly inhibits CD4-MHC Class II interactions. |
| CD4 (mouse) | GK1.5 | Isolation and depletion of CD4+ T cells, blocking of ligand binding to CD4. |
| CD42b | HIP1 | The antibody HIP1 inhibits the ristocetin-dependent binding of von Willebrand Factor (vWF) to platelets and ristocetin-induced platelet agglutination. |
| CD43 | MEM-59 | The antibody MEM-59 activates T lymphocytes and also induces apoptosis in hemopoietic progenitor cells. |
| CD50 | MEM-04 | The antibody MEM-04 blocks DC-SIGN (CD209) binding to ICAM-3 (epitope in D1). |
| CD53 | MEM-53 | The antibody MEM-53 induces activation of monocytes and B lymphocytes. |
| CD58 | MEM-63 | The antibody MEM-63 inhibits CD2/CD58 interactions. |
| CD59 | MEM-129 | The antibody MEM-129 activates T cells. |
| CD69 | FN50 | When stimulating peripheral blood T cells, FN50 antibody together with TPA synergistically increases cell volume and RNA/DNA synthesis. Addition of FN50 to stimulated peripheral blood B cells has similar, but weaker effect. |
| CD81 | M38 | In human MOLT-4 T-cell line the antibody M38 inhibits syncytium formation induced by coculture with human T-cell leukemia virus type 1 (HTLV-1)-positive human T-cell lines. |
| CD86 | BU63 | The antibody BU63 blocks mixed lymphocyte reaction (MLR) and binding of soluble CTLA-4 (CD152)-mulg fusion protein to CD86 (B7-2). |
| CD8a (mouse) | 53-6.7 | Isolation and depletion of CD8+ cells, blocking of cytotoxicity, inhibition of CD8+ T cell proliferation. |
| CD9 | MEM-61 | The antibody MEM-61 induces FcγR-dependent platelet aggregation. |
| CD9 (bovine) | IVA50 | The antibody IVA50 activates bovine thrombocytes. |
| CD90.2 / Thy-1.2 (mouse) | 1aG4/C5 | The bound of antibody 1aG4/C5 to the transfected mast cells induces the activation processes which are similar, but not identical, to the antigen activation of IgE stimulated cells. Other studies approve that the antibody 1aG4/C5 precipitates complexes with Lyn protein tyrosine kinase. |
| CD95 / Fas | UT-1 | The antibody UT-1 induces Fas-mediated apoptosis. |
| HIV protease | 1696 | The antibody 1696 strongly inhibits the enzyme activity of HIV-1 and HIV-2 proteases. |
| HLA-Class I | W6/32 | The antibody W6/32 is suitable as a positive control for HLA tissue typing. |
| HLA-G | 87G | Application note: The antibody 87G blocks interaction of HLA-G with inhibitory receptors. |
| Insulin | IN-05 | The antibody IN-05 blocks binding of insulin to the receptor. |
| Ly6G (mouse) | RB6-8C5 | Neutrophil depletion |
| TCR beta (Vbeta5.3-related) | MEM-262 | Activates T cells (V beta 5-related subset) |
| TCR beta (mouse) | H57-597 | In vitro T cell stimulation; In vivo T cell depletion |
| Transferrin | HTF-14 | The antibody HTF-14 blocks binding of transferrin to the receptor. |